CELLINK is announcing the BIO X6, a six-printhead bioprinting platform that enables users to combine more materials, cells and tools than any other system on the market. The product is the only bioprinter that combines six printheads with CELLINK’s patented Clean Chamber Technology and intelligent exchangeable printhead technology.
CELLINK’s mission is to provide innovative technologies to aid the cutting-edge research of scientists worldwide. The BIO X6 is an excellent platform for meeting the needs of advanced tissue engineers, regenerative medicine labs and cancer biologists that require high-throughput bioprinting and dispensing.
“Organs and tissues are comprised of many different cell types. With the BIO X6, users can combine six or more cell types to print advanced organ and tissue models.
The BIO X6 gives the user freedom to combine multiple materials in one print, and the capability to create more complex architectures.
Being able to use different pressures, temperatures and printing methods simultaneously in six different positions is revolutionary. Users can mix the cells in each printhead with a tailored bioink, providing the cells with the biological environment they need to achieve the desired architecture.”
-Itedale Namro Redwan,Chief Scientific Officer at CELLINK.
The new technology, based on CELLINK’s award-winning BIO X platform, was developed by CELLINK in order to advance research and clinical applications in the bioprinting field. The system comes with a movable arm mount, enabling multiple possibilities in one system. Users can either control through a Wi-Fi connection or through a detachable tablet on the movable arm mount.
The new product is now available to order. Contact firstname.lastname@example.org speak with a local sales representative.
For more information, please contact:
CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: email@example.com.